Time-dependent endpoints as predictors of overall survival in multiple myeloma

被引:19
作者
Felix, Jorge [1 ]
Aragao, Filipa [1 ]
Almeida, Joao M. [1 ]
Calado, Frederico J. M. [1 ]
Ferreira, Diana [1 ]
Parreira, Antonio B. S. [2 ]
Rodrigues, Ricardo [3 ]
Rijo, Joao F. R. [4 ]
机构
[1] Exigo Consultores, P-2860021 Alhos Vedros, Portugal
[2] Portuguese Oncol Inst Lisboa, Lisbon, Portugal
[3] Univ Lisbon, Fac Pharm, P-1699 Lisbon, Portugal
[4] Hosp Egas Moniz, Lisbon, Portugal
关键词
Multiple myeloma; Overall survival; Survival predictors; Time-dependent endpoint; Time to progression; PROGRESSION-FREE-SURVIVAL; PREDNISONE PLUS THALIDOMIDE; METASTATIC COLORECTAL-CANCER; HEALTH TECHNOLOGY-ASSESSMENT; RANDOMIZED CONTROLLED-TRIALS; STEM-CELL TRANSPLANTATION; LARGE-SAMPLE PROPERTIES; PHASE-III TRIALS; ELDERLY-PATIENTS; CLINICAL-TRIALS;
D O I
10.1186/1471-2407-13-122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. Methods: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman's rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. Results: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7-3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. Conclusion: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation.
引用
收藏
页数:12
相关论文
共 92 条
  • [1] Clinically relevant end points and new drug approvals for myeloma
    Anderson, K. C.
    Kyle, R. A.
    Rajkumar, S. V.
    Stewart, A. K.
    Weber, D.
    Richardson, P.
    [J]. LEUKEMIA, 2008, 22 (02) : 231 - 239
  • [2] [Anonymous], ASH ANN M
  • [3] [Anonymous], BLOOD
  • [4] [Anonymous], 2010, SURV EP END RES SEER
  • [5] [Anonymous], 2011, HAEMATOLOGICA
  • [6] [Anonymous], 2010, BLOOD
  • [7] [Anonymous], 2010, Cancer facts and figures
  • [8] [Anonymous], HAEMATOLOGICA
  • [9] Surrogate endpoints: Wishful thinking or reality?
    Baker, Stuart G.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08): : 502 - 503
  • [10] Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
    Beksac, Meral
    Haznedar, Rauf
    Firatli-Tuglular, Tulin
    Ozdogu, Hakan
    Aydogdu, Ismet
    Konuk, Nahide
    Sucak, Gulsan
    Kaygusuz, Isik
    Karakus, Sema
    Kaya, Emin
    Ali, Ridvan
    Gulbas, Zafer
    Ozet, Gulsum
    Goker, Hakan
    Undar, Levent
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) : 16 - 22